Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

被引:372
作者
Stevens, DL
Herr, D
Lampiris, H
Hunt, JL
Batts, DH
Hafkin, B
机构
[1] Vet Affairs Med Ctr, Infect Dis Sect, Boise, ID 83702 USA
[2] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA
[3] Washington Hosp Ctr, Surg Crit Care Dept, Washington, DC 20010 USA
[4] Vet Adm Med Ctr, Dept Med, Infect Dis Sect, San Francisco, CA 94121 USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Univ Texas, SW Med Ctr, Div Infect Dis, Dallas, TX USA
[7] Pharmacia Corp, Peapack, NJ USA
关键词
D O I
10.1086/340353
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Linezolid, the first available member of a new antibiotic class, the oxazolidinones, is broadly active against gram-positive bacteria, including drug-resistant strains. In this randomized, open-label trial, hospitalized adults with known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with linezolid (600 mg twice daily; n = 240) or vancomycin (1 g twice daily; n = 220) for 7-28 days. S. aureus was isolated from 53% of patients; 93% of these isolates were MRSA. Skin and soft-tissue infection was the most common diagnosis, followed by pneumonia and urinary tract infection. At the test-of-cure visit (15-21 days after the end of therapy), among evaluable patients with MRSA, there was no statistical difference between the 2 treatment groups with respect to clinical cure rates (73.2% of patients in the linezolid group and 73.1% in the vancomycin group) or microbiological success rates (58.9% in the linezolid group and 63.2% in the vancomycin group). Both regimens were well tolerated, with similar rates of adverse events.
引用
收藏
页码:1481 / 1490
页数:10
相关论文
共 54 条
[1]   Nosocomial methicillin-resistant and methicillin-susceptible, Staphylococcus aureus primary bacteremia:: At what costs [J].
Abramson, MA ;
Sexton, DJ .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (06) :408-411
[2]   Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin [J].
Ariza, J ;
Pujol, M ;
Cabo, J ;
Peña, C ;
Fernández, N ;
Liñares, J ;
Ayats, J ;
Gudiol, F .
LANCET, 1999, 353 (9164) :1587-1588
[3]   Bird's-eye view of nosocomial infections in medical ICU: Blue bugs, fungi, and device-days [J].
Bonten, MJM ;
Weinstein, RA .
CRITICAL CARE MEDICINE, 1999, 27 (05) :853-854
[4]   Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections [J].
Brickner, SJ ;
Hutchinson, DK ;
Barbachyn, MR ;
Manninen, PR ;
Ulanowicz, DA ;
Garmon, SA ;
Grega, KC ;
Hendges, SK ;
Toops, DS ;
Ford, CW ;
Zurenko, GE .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :673-679
[5]   Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci [J].
Carbon, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 :31-36
[6]  
Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P813
[7]   Risk factors for ICU-acquired pneumonia [J].
Cook, DJ ;
Kollef, MH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1605-1606
[8]  
Dresser LD, 1998, PHARMACOTHERAPY, V18, P456
[9]   In vitro activities of new oxazolidinone antimicrobial agents against enterococci [J].
Eliopoulos, GM ;
Wennersten, CB ;
Gold, HS ;
Moellering, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (07) :1745-1747
[10]  
EMBIL J, 1994, INFECT CONT HOSP EP, V15, P646